Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pre-therapy inflammation and coagulation activation and long-term CD4 count responses to the initiation of antiretroviral therapy.
Achhra AC, Phillips A, Emery S, MacArthur RD, Furrer H, De Wit S, Losso M, Law MG; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Strategic Management of Antiretroviral Therapy (SMART) and Flexible Initial Retrovirus Suppressive Therapies (FIRST) study groups. Achhra AC, et al. Among authors: macarthur rd. HIV Med. 2015 Aug;16(7):449-54. doi: 10.1111/hiv.12258. Epub 2015 May 11. HIV Med. 2015. PMID: 25959989 Free PMC article. Clinical Trial.
Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT).
Pett SL, Carey C, Lin E, Wentworth D, Lazovski J, Miró JM, Gordin F, Angus B, Rodriguez-Barradas M, Rubio R, Tambussi G, Cooper DA, Emery S; INSIGHT-ESPRIT Study Group. Pett SL, et al. HIV Med. 2011 Apr;12(4):219-27. doi: 10.1111/j.1468-1293.2010.00875.x. Epub 2010 Aug 31. HIV Med. 2011. PMID: 20812949 Free PMC article. Clinical Trial.
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. HIV Med. 2015. PMID: 25711317 Free PMC article. No abstract available.
Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy.
MacArthur RD, Perez G, Walmsley S, Baxter JD, Mullin CM, Neaton JD; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) 042/045; Canadian HIV Trials Network (CTN) 102 Protocol Teams. MacArthur RD, et al. HIV Clin Trials. 2005 May-Jun;6(3):127-35. doi: 10.1310/A9B9-RQD7-U8KA-503U. HIV Clin Trials. 2005. PMID: 16192247 Clinical Trial.
Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons.
MacArthur RD, Chen L, Peng G, Novak RM, van den Berg-Wolf M, Kozal M, Besch L, Yurik T, Schmetter B, Henley C, Dehlinger M; CPRCA 058 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. MacArthur RD, et al. HIV Clin Trials. 2004 Nov-Dec;5(6):361-70. doi: 10.1310/WEQG-QTHL-DL3X-FTXC. HIV Clin Trials. 2004. PMID: 15682349 Clinical Trial.
A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Hullsiek KH, Kozal MJ, van den Berg-Wolf M, Henely C, Schmetter B, Dehlinger M; CPCRA 058 Study Team; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). MacArthur RD, et al. Lancet. 2006 Dec 16;368(9553):2125-35. doi: 10.1016/S0140-6736(06)69861-9. Lancet. 2006. PMID: 17174704 Clinical Trial.
Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons.
van den Berg-Wolf M, Hullsiek KH, Peng G, Kozal MJ, Novak RM, Chen L, Crane LR, Macarthur RD; CPCRA 058 Study Team, the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA), and The International Network for Strategic Initiative in Global HIV Trials (INSIGHT). van den Berg-Wolf M, et al. Among authors: macarthur rd. HIV Clin Trials. 2008 Sep-Oct;9(5):324-36. doi: 10.1310/hct0905-324. HIV Clin Trials. 2008. PMID: 18977721 Clinical Trial.
The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naïve participants started on three different antiretroviral therapy strategies.
Kozal MJ, Hullsiek KH, Macarthur RD, Berg-Wolf Mv, Peng G, Xiang Y, Baxter JD, Uy J, Telzak EE, Novak RM; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Kozal MJ, et al. Among authors: macarthur rd. HIV Clin Trials. 2007 Nov-Dec;8(6):357-70. doi: 10.1310/hct0806-357. HIV Clin Trials. 2007. PMID: 18042501 Clinical Trial.
80 results